Press Releases

Gilead Sciences announces acquisition of Phenex Pharmaceuticals’ development program for Non-Alcoholic Steatohepatitis (NASH) and other liver diseases.
Gilead Sciences, Inc. (Nasdaq: GILD) and Phenex Pharmaceuticals AG ...
Gilead Sciences gibt die Akquisition von Phenex Pharmaceuticals’ Entwicklungsprogramm in NASH (Nicht-Alkoholischer Steatohepatitis) und anderen Lebererkrankungen bekannt.
Gilead Sciences, Inc. (Nasdaq: GILD) und Phenex Pharmaceuticals AG ...
Phenex enters into a Research Collaboration and License Agreement with Janssen
for Autoimmune and Chronic Inflammatory Disorders
Phenex will receive an upfront payment and is eligible ...
Phenex und Janssen vereinbaren eine Forschungskooperation in Verbindung
mit einem Lizenzabkommen auf dem Gebiet von
Autoimmun- und Chronisch Entzündlichen Erkrankungen
Phenex erhält eine Upfront-Zahlung und kann erfolgs- und ...
Phenex reports successful completion of Phase I Studies with FXR-Agonist Px-102
and publishes research progress in two independent papers
On the back of the good scientific news, Phenex raises 5 Mio Euro...
Phenex schließt erfolgreich die Phase I - Entwicklung ihres FXR-Agonisten Px-102 ab
und publiziert neue Forschungsergebnisse
Auf Basis dieser ermutigenden Datenlage wirbt Phenex 5 Mio Euro...
Phenex initiates Phase I first-in-man study with its clinical development candidate Px-102
The FXR agonist Px-102 might open new avenues for the treatment of Non-Alcoholic Steatohepatitis (NASH)...
Phenex beginnt die klinische Phase I Erstanwendungsstudie für den Entwicklungskandidaten Px-102
Der FXR-Agonist Px-102 eröffnet neue Behandlungsmöglichkeiten für Nichtalkoholische Steatohepatitis (NASH)...
Phenex wins Prof. Dr. med Dr. rer. nat. Werner Kramer as scientific advisor
Phenex and Prof Kramer will jointly develop Phenex´ FXR agonist Px-102...
Phenex gewinnt Prof. Dr. med Dr. rer. nat. Werner Kramer als wissenschaftlichen Berater
Phenex und Prof. Kramer gehen gemeinsam die klinische Entwicklung von Px-102...

Prof Kramer
Phenex closes 6 Mio € Series C financing round
Phenex receives 1.4 Mio Euro BioChance Grant.
Phenex AG develops novel indications for FXR-targeted drugs and wins Prof. Dr. Michael Trauner as...
Prof. Dr. Bernd Wetzel becomes Head of Phenex´ Scientific Advisory Board.
Phenex Pharmaceuticals AG today announced that Prof. Dr. Bernd Wetzel will become...
Phenex AG and Biogen Idec enter into a milestone-based target to lead collaboration.
Biogen Idec uses Phenex' expertise to identify...
Phenex AG closes 11,5 M USD (8,2 M Euro) financing round.
A syndicate of institutional and private investors...
Phenex AG provides drug profiling services to Sanofi Aventis.
Phenex uses its Nuclear Receptor assay battery...
Phenex AG provides compound profiling services to Bayer-Schering Pharma AG.
Phenex uses its SNuRM® platform to support...
Phenex AG obtains four patents relevant for its drug discovery efforts.
The nuclear receptor-based drug discovery company starts...
Phenex AG closes first equity funding round.
Phenex Pharmaceuticals announced today the closing of its first equity financing round...
Phenex AG widens customer base, maintains profitability and recruits further laboratory staff.
Additional business by acquiring a list of new customers worldwide...
Phenex licences Nuclear Receptor Research Toolbox to Roche.
Fruitful collaboration with Roche is continued...
Phenex launches RE-PheXTM.
A unique software tool for the genome wide prediction of candidate target genes...
Phenex acquires Nuclear Receptor Assets from LION.
Phenex founders’ team performs a “true” management buy-out...
Phenex and Roche enter into research collaboration.
Phenex is tasked to profile novel Roche compounds using
the SNuRM® Technology...